therapy news

Racial gaps exist in women’s heart-health awareness, women’s knowledge of heart attack warning signs requires attention and nearly half of women report they would not call 9-1-1 if they were having heart attack symptoms, according to new research published in Circulation: Cardiovascular Quality and Outcomes, a journal of the American Heart Association.

The U.S. Food and Drug Administration today approved Tykerb (lapatinib) in combination with Femara (letrozole) to treat hormone positive and HER2-positive advanced breast cancer in postmenopausal women for whom hormonal therapy is indicated.

HAART can reduce HIV levels to below detectable numbers. But, some small amounts of virus evade drug therapy and stay inactive in a so-called latent form, in immune system cells.

Siemens will sell its 25 percent stake in Dräger Medical AG & Co. KG to majority shareholder Dräger.

Medical professionals, expecting parents can see fetus in unprecedented detail with 3D ultrasound technology and NVIDIA 3D Vision Glasses

On the eve of World AIDS Day, WHO is releasing new recommendations on treatment, prevention and infant feeding in the context of HIV, based on the latest scientific evidence.

People with untreated Obstructive Sleep Apnea may be at higher risk - for serious health hazards such as weight gain, diabetes and high blood pressure

Royal Philips Electronics (NYSE: PHG, AEX: PHI) and GlyGenix Therapeutics, Inc. (Woodbridge, Connecticut, USA) today announced a joint research agreement to explore the feasibility of using ultrasound technologies for gene therapy.

Siemens Healthcare is expanding its portfolio for cancer therapy by partnering with IMPAC Medical Systems, Inc. (IMPAC) which includes an extension of its software distribution agreement to 2016 and adding the MOSAIQÒ software to its oncology portfolio.

Factbook Provides Authoritative Industry Metrics For The Key Stages In Drug Development

A multicenter research team has announced encouraging results for an experimental therapy using elements of the body's immune system to improve cure rates for children with neuroblastoma, a challenging cancer of the nervous system.

Schering-Plough Corporation (NYSE: SGP) today announced that the U.S. Food and Drug Administration (FDA) has approved new labeling for PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combination therapy for treating chronic hepatitis C in patients 3 years of age and older with compensated liver disease.

Compounds extracted from green vegetables such as broccoli and cabbage could be a potent drug against melanoma, according to cancer researchers. Tests on mice suggest that these compounds, when combined with selenium, target tumors more safely and effectively than conventional therapy.

For orthopaedic researcher Joyce Keyak, Ph.D., finding ways to battle breast cancer is a personal as well as a professional mission. Her cousin died from the disease several years ago. Dr. Keyak still remembers the incredible pain her cousin experienced when the cancer spread to her spine.

Worldwide, nearly 2 million people per year die from diarrhea, the vast majority of them in poor countries in Africa and Asia. The disease accounts for 18 percent of all deaths among children -- and yet is almost always preventable with proper treatment.

A new study demonstrates that a chemical mediator in the blood that influences immune cell migration also plays a key role in maintaining the balance between the build-up and breakdown of bones in the body.

Researchers have discovered a way to get another bonus from the implementation of electronic medical records: testing the efficacy of treatments for disease.

Researchers at Duke University Medical Center have identified a variation in a particular gene that increases a person's susceptibility to early coronary artery disease.

The U.S. Food and Drug Administration recently approved the injectable drug degarelix, the first new drug in several years for prostate cancer.

University of Cincinnati (UC) researchers have discovered a new therapy for transplant patients, targeting the antibody-producing plasma cells that can cause organ rejection.